"The NHS wastes billions on “me too” drugs that confer little or no added therapeutic benefit. James Moon and colleagues propose a way to restructure healthcare prescribing to get better value for money and persuade drug companies to invest in developing innovative drugs."
Getting better value from the NHS drug budget
JC Moon, AS Flett, BB Godman, AM Grosso, AS Wierzbicki
British Medical Journal, 2010; 341:c6449
Read more here.
An accompanying commentary, by David Phizackerley, is available here.
No comments:
Post a Comment